Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ATM V1268fs |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ATM V1268fs | appendix cancer | predicted - sensitive | Elimusertib | Case Reports/Case Series | Actionable | In a Phase I trial, Elimusertib (BAY1895344) treatment resulted in a partial response with a 35% decrease in tumor size in a patient with appendix cancer harboring ATM V1268fs, treatment was ongoing at 472 days (PMID: 32988960; NCT03188965). | 32988960 |